



11/11/2025

A CRASH COURSE IN OHDSI

Renske Los, PhD

Deputy Head of Medical Informatics, Erasmus MC

National Nodes Coordinator, OHDSI Europe

Co-Lead [OHDSI.NL](https://ohdsi.nl)

IN THE NEXT 20 MINUTES...



WHAT IS OHDSI?
WHAT IS OMOP?



WHAT'S IN IT FOR
YOU?



HOW TO GET
INVOLVED

WHAT IS OHDSI?

Standard analytics




OMOP Common Data Model

Active global community

*OHDSI is a **fun** way to collaborate with an amazing community across the globe to collectively advance science and improve the lives of patients around the world.*


IF YOU DO NOT HAVE OMOP, RESEARCH BE LIKE...



Why Most Published Research Findings Are False

Researcher: David A. Prentice



It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.



Why Most Published Research Findings Are False

Researcher: David A. Prentice



It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.



Why Most Published Research Findings Are False

Researcher: David A. Prentice

It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.



Why Most Published Research Findings Are False

Researcher: David A. Prentice


It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.



Why Most Published Research Findings Are False

Researcher: David A. Prentice



It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.



Why Most Published Research Findings Are False

Researcher: David A. Prentice

It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.




Why Most Published Research Findings Are False

Researcher: David A. Prentice


It is a common belief that most published research findings are false. This is a reasonable belief, given the fact that the vast majority of research findings are not replicated. The reason for this is that the research community is biased towards publishing positive results, while ignoring negative results. This leads to a distorted view of the world, where only the positive results are seen, and the negative results are ignored. This is a problem because it leads to a lack of understanding of the true nature of the world, and it can lead to poor decisions being made based on the research findings.

IF YOU HAVE OMOP, RESEARCH BE LIKE...

The OHDSI analysis pipeline simplified



REAL-WORLD EVIDENCE GENERATION USING OMOP CDM



Standardized data enables standardized analytics!

Common format
& terminology
Single curation,
multiple use


Standard input & output
Parametrized choices

OMOP COMMON DATA MODEL (CDM) v5.4

Syntactic
interoperability



OMOP CDM



Semantic
interoperability

BENEFITS OF STANDARDIZED DATA & ANALYTICS

1. Large-scale evidence

Federated analysis allows multi-database studies without compromising privacy

2. Rapid response


Large time savings through data readiness and pre-developed tooling

3. Scalable & reproducible

Tooling can be reused across databases and disease domains

→ **Reliable evidence**

OHDSI Tools (OPEN-SOURCE)



WHAT'S IN IT FOR YOU?


QUESTIONS ASKED ACROSS THE PATIENT JOURNEY

Clinical characterization

Which patients take which treatments?

How many patients experienced complications?

Conditions
Drugs
Procedures
Measurements



Patient-level prediction

What is the probability that I will develop a given disease?

What is the probability that I will experience an (adverse) outcome?

Population-level effect estimation

Does treatment cause an outcome?

Does one treatment lead to a better outcome than the alternative?




TREATMENT PATTERNS

IPCI (NL) - Asthma

Outer layers show
2nd and 3rd treatment

Inner circle shows 1st
treatment, SABA most
common, followed by ICS

Patients that did not receive
treatment during the follow-up
time (> 3 years)





- Type 2 Diabetes Mellitus**

CCA

Metformin

Glipizide

pioglitazone

sitagliptin

glimepiride

Glipizide

rosiglitazone

Glyburide

Insulin, Glargine, Human

exenatide

Insulin, Aspart, Human

saxagliptin

CPRD

JMDC

Hypertension

Hydrochlorothiazide

Lisinopril

Metoprolol

Amlodipine

Furosemide

Losartan

Atenolol

valsartan

carvedilol

Tiamterene

Diltiazem

Ramipril

benazepril

olmesartan

Spironolactone

Clonidine

CUMC

INPC

MDCR

Depression

Citalopram

Bupropion

Sertraline

Escitalopram

Fluoxetine

Trazodone

venlafaxine

duloxetine

Paroxetine

Amitriptyline

Mirtazapine

Desvenlafaxine

Nortriptyline

Doxepin

MDCD

GE

OPTUM

A Hospital CDM (USA)
Pre-vaccination
Vaccinated

B IMASIS (ES)
Pre-vaccination
Vaccinated

C CPRD (UK)

D LPD FRANCE (FR)

E SIDIAP (ES)





F DA Germany (DE)

G IPCI (NL)

H OpenClaims (USA)


Legend:

- Vitamin K antagonists
- Dabigatran
- Direct thrombin inhibitors excl. dabigatran
- Direct factor Xa inhibitors
- Other anticoagulants
- Fibrinogen
- Heparins
- Immunoglobulins
- Plasma exchange/platelet transfusion
- Platelet aggregation inhibitors
- Rituximab
- Systemic corticosteroids
- Thrombolytic/fibrinolytic enzymes
- Thrombolytic procedures
- Other

 United States: CCAE Claims N = 572,637 Treated 85.5%		 United States: Medical Claims N = 127,803 Treated 66.8%		
 United States: Medicare Claims N = 48,544 Treated 79.0%		 Estonia: EHIF Claims N = 22,949 Treated 93.0%		
 United Kingdom: CPRD EHR, GP N = 44,983 Treated 93.1%		 Spain: SIDIAP EHR, GP N = 85,088 Treated 92.7%		
 Netherlands: IPCI EHR, GP N = 10,793 Treated 84.8%		 South Korea: AUSOM EHR, Hospital N = 2,579 Treated 82.9%		

- **A lot of potential:** use the OHDSI data network to get high-level insight in current treatment practices across different *patient populations, care settings, and countries* in Europe (and globally)

OHDSI LEGEND HYPERTENSION STUDY



Results: From 21.6 million unique antihypertensive new users, we generate 6 076 775 effect size estimates for 699 872 research questions on 12 946 treatment comparisons. Through propensity score matching, we achieve balance on all baseline patient characteristics for 75% of estimates, observe 95.7% coverage in our effect-estimate 95% confidence intervals, find high between-database consistency, and achieve transitivity in 84.8% of triplet hypotheses. Compared with meta-analyses of RCTs, our results are consistent with 28 of 30 comparisons while providing narrower confidence intervals.

Figure 3. Comparisons of single-drug hypertension treatments in randomized controlled trials (left) and in LEGEND (right). Each circle represents an ingredient. Color groupings indicate drug classes. A line between circles indicates the 2 drugs are compared in at least 1 study.



A GLOBAL NETWORK


To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care

OHDSI Collaborators

- 4,294 collaborators
- 83 countries
- 21 time zones
- 6 continents

OMOP CDM Users By The Numbers

- 544 data sources
- 54 countries
- 974 million unique patient records (12% of world's population)




www.ohdsi.org




NETWORK DATA PARTNERS & SERVICE PROVIDERS

187 Data partners

≈ 370 million
patients mapped to
OMOP CDM in 29
European countries



64 'EHDEN-certified' SMEs across Europe



<https://www.ehden.eu/business-directory/>

**HOW TO GET INVOLVED
OR LEARN MORE**

EU NATIONAL NODES


An OHDSI Europe National Node is a collection of organizations within a member country.

The Node builds on the strengths of the **stakeholders** and **scientific communities** of that country.


The goal of national nodes is to facilitate national and international collaborations.

National nodes were started as part of the EHDEN project and in collaboration with the OHDSI Europe Chapter.

<https://ohdsi-europe.org/index.php/national-nodes>



WHATS GOING ON IN THE NODES






OHDSI WORKGROUPS



OHDSI

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

See an area where you want to contribute? Please Join The Journey!



Join A Workgroup

Meeting Schedule

Workgroup Tips

Get to Know the OHDSI Workgroups

[Africa Chapter](#)
[APAC](#)
[ATLAS/WebAPI](#)
[Clinical Trials](#)
[Common Data Model](#)
[CDM Survey Subgroup](#)
[CDM Vocabulary Subgroup](#)
[Dentistry](#)
[Early-Stage Researchers](#)
[Electronic Animal Health Records](#)
[Eye Care & Vision Research](#)
[FHIR and OMOP](#)

[Generative AI & Analytics in Healthcare \(GAIA\)](#)
[GIS – Geographic Information System](#)
[HADES](#)
[Health Equity](#)
[Healthcare Systems](#)
[Industry](#)
[Latin America](#)
[Medical Devices](#)
[Medical Imaging](#)
[Methods Research](#)
[Natural Language Processing](#)
[Network Data Quality](#)

[Oncology](#)
[Open-Source Community](#)
[Patient-Level Prediction](#)
[Perinatal and Reproductive Health](#)
[Phenotype Development & Evaluation](#)
[Psychiatry](#)
[Rehabilitation](#)
[Registry](#)
[Steering Group](#)
[Surgery and Perioperative Medicine](#)
[Themis](#)
[Vaccine Vocabulary](#)

Online

Global: Every Tuesday @ 17:00 CET

Europe: Every 2nd Thursday @ 13:00 CET



Upcoming Europe Community Calls

Date	Topic
Sept. 11	Europe Community Call Introduction / DARWIN EU Update
Oct. 9	Meet the New National Nodes
Nov. 13	Patient-Reported Outcome Measures (PROMs)
Dec. 11	Vocabularies in Europe

LEARNING MORE – EHDEN ACADEMY



- Free online educational resource
- More than 5,350 active learners across 108 countries

Getting Started

EHDEN Foundation

Patient
Organizations: Real
World Data and Real
World Research

OMOP CDM and
Standardized
Vocabularies

ATLAS

Infrastructure

Extract, Transform
and Load

Introduction to Usagi
& Code Mappings for
an ETL

OHDSI-in-a-Box

ETL Learning
Pathway: Data
Partner & SME Real
World Use Cases

10 Minute Tutorial:
PheValuator

10 Minute Tutorial:
ATHENA

Open Science & FAIR
Principles

Introduction to Data
Quality

Phenotype
Definition,
Characterisation
and Evaluation

Population-level
Effect Estimation

Patient-Level
Prediction

R for Patient-level
Prediction

Applied Cost-
Effectiveness
Modeling with R

Assessing
healthcare using
outcomes that
matter to patients

OHDSI2022 Tutorial
- Creating Cohort
Definitions

OHDSI2022 Tutorial
- OMOP Common
Data
Model/Vocabulary

One hour of your
time: The
Phenotyping
Problem


Health Technology
Assessment

LEARNING MORE – THE BOOK OF OHDSI

A comprehensive guide to



The OHDSI
Community




Uniform Data
Representation




Data Analytics



Evidence Quality



OHDSI studies



LEARNING MORE – YOUTUBE CHANNEL




Community call
meetings



Tool tutorials



Workshops



Previous events





**EUROPEAN OHDSI
SYMPOSIUM**
Rotterdam



18 - 20 April 2026

2026 ROTT

